_____________________
SFnano French society for nanomedicine
The French Nanomedicine Society (SFNano) was launched on January 1, 2014 with the desire to continue to best represent the actors in the field of Nanomedicine in France.
Initially, Thematic Group for Research on Vectorization (GTRV), SFNano wishes to work in continuity while rising to the challenges of today.
The main objective of this non-profit association, under the French law of 1901, is to promote the progress and dissemination of knowledge in the field of nanomedicine, and to encourage exchanges between players in the field in the academic and industrial sectors, in France and beyond, with our European neighbors.
“The term nanomedicine, as defined by the ETPN, includes any nanotechnology whose purpose is diagnosis, therapy, imaging or theranostics. It also includes all aspects of vectorization and delivery, i.e., all approaches to transport biologically active molecules to their biological target (molecular vectors, nanoparticles, microparticles, “smart” systems, implants, tissue reconstruction…).”
_____________________
Also to be read
CNRS honors Néovacs and UTCBS, united for a therapeutic RNA vaccine against asthma
Suresnes, August 29, 2024 - 8am CET - Neovacs (Euronext Growth Paris : ALNEV), a preclinical-stage biopharmaceutical company developing novel therapies for inflammatory and autoimmune diseases, is honored to be listed among the latest CNRS publications following the...
Publication in Advanced Science of Preclinical tests obtained with a pFAR plasmid
Gene Electrotransfer via Conductivity-Clamped Electric Field Focusing Pivots Sensori-Motor DNA Therapeutics: “A Spoonful of Sugar Helps the Medicine Go Down” https://doi.org/10.1002/advs.202401392
Khair Alareth, Caroline Roques and Nasir Arafath with Nathalie Mignet to present UTCBS’s work at the Controlled release society international congress in Bologna.
UTCBS presents its work at the international congress of the "controlled release society" in Bologna. The UTCBS team has shown the interest of nanoparticles both for the imaging of ROS in vivo and the promotion of antioxydant therapeutic activity. Caroline Roques...
The Alnylam Pharmaceuticals 2024 “Interfering RNA & Rare Diseases” Prize has been awarded to Virginie Escriou,
The Alnylam Pharmaceuticals 2024 “Interfering RNA & Rare Diseases” Prize has been awarded to Virginie Escriou,